<?xml version="1.0" encoding="UTF-8"?>
<table id="PMC7059311/table_4" xmlns="http://www.w3.org/1999/xhtml">
 <caption>
  <label>Table 4</label>
  <p>Safety profile of DAAs regimens</p>
 </caption>
 <thead>
  <tr>
   <th colspan="1" rowspan="1" id="0-0-."/>
   <th colspan="1" rowspan="1" id="0-1-.">Patients 
    <i>(N = 144)</i>
   </th>
   <th colspan="1" rowspan="1" id="0-2-.">Group A 
    <i>(N = 101)</i>
   </th>
   <th colspan="1" rowspan="1" id="0-3-.">Group B 
    <i>(N = 43)</i>
   </th>
   <th colspan="1" rowspan="1" id="0-4-.">
    <b>
     <i>p-</i>
    </b>value 
   </th>
  </tr>
 </thead>
 <tbody>
  <tr>
   <td>
    <b>At least 1 adverse event,</b>
    <b>
     <i>n</i>
    </b>
    <b>(%)</b>
   </td>
   <td>60 (41,6%)</td>
   <td>49 (48.5%)</td>
   <td>11 (25.6%)</td>
   <td>
    <b>0.015</b>
   </td>
  </tr>
  <tr>
   <td>
    <b>&gt; 2 adverse events,</b>
    <b>
     <i>n</i>
    </b>
    <b>(%)</b>
   </td>
   <td>7 (4.8%)</td>
   <td>6 (5.9%)</td>
   <td>1 (2.3%)</td>
   <td>0.674</td>
  </tr>
  <tr>
   <td>
    <b>Severe adverse events,</b>
    <b>
     <i>n</i>
    </b>
    <b>(%)</b>
   </td>
   <td>10 (6.9%)</td>
   <td>8 (7.9%)</td>
   <td>2 (4.6%)</td>
   <td>0.723</td>
  </tr>
  <tr>
   <td>
    <b>Adverse events leading to discontinuation,</b>
    <b>
     <i>n</i>
    </b>
    <b>(%)</b>
   </td>
   <td>3 (2.1%)</td>
   <td>2 (1.9%)</td>
   <td>1 (2.3%)</td>
   <td>1.000</td>
  </tr>
  <tr>
   <td>
    <b>Skin reactions</b>
    <sup>
     <b>a</b>
    </sup>
    <b>,</b>
    <b>
     <i>n</i>
    </b>
    <b>(%)</b>
   </td>
   <td>11 (7.6%)</td>
   <td>9 (8.9%)</td>
   <td>2 (4.6%)</td>
   <td>0.506</td>
  </tr>
  <tr>
   <td>
    <b>Anemia,</b>
    <b>
     <i>n</i>
    </b>
    <b>(%)</b>
   </td>
   <td>7 (4.8%)</td>
   <td>5 (4.9%)</td>
   <td>2 (4.6%)</td>
   <td>1.000</td>
  </tr>
  <tr>
   <td>
    <i>Requiring erythropoietin</i>
   </td>
   <td>2 (1.3%)</td>
   <td>2 (1.9%)</td>
   <td>0</td>
   <td/>
  </tr>
  <tr>
   <td>
    <i>Requiring RBV dose adjustment</i>
   </td>
   <td>4 (2.7%)</td>
   <td>2 (1.9%)</td>
   <td>2 (4.6%)</td>
   <td/>
  </tr>
  <tr>
   <td>
    <i>Requiring hospitalization</i>
   </td>
   <td>1 (0.7%)</td>
   <td>1 (0.9%)</td>
   <td>0</td>
   <td/>
  </tr>
  <tr>
   <td>
    <b>Gastrointestinal toxicity</b>
    <sup>
     <b>b</b>
    </sup>
    <b>,</b>
    <b>
     <i>n</i>
    </b>
    <b>(%)</b>
   </td>
   <td>11 (7.6%)</td>
   <td>9 (8.9%)</td>
   <td>2 (4.6%)</td>
   <td>0.506</td>
  </tr>
  <tr>
   <td>
    <b>Cardiac disorders</b>
    <sup>
     <b>c</b>
    </sup>
    <b>,</b>
    <b>
     <i>n</i>
    </b>
    <b>(%)</b>
   </td>
   <td>6 (4.1%)</td>
   <td>5 (4.9%)</td>
   <td>1 (2.3%)</td>
   <td>0.669</td>
  </tr>
  <tr>
   <td>
    <b>Neurological symtomps,</b>
    <b>
     <i>n</i>
    </b>
    <b>(%)</b>
   </td>
   <td>26 (18.0%)</td>
   <td>20 (19.8%)</td>
   <td>6 (13.9%)</td>
   <td>0.483</td>
  </tr>
  <tr>
   <td>
    <i>Asthenia</i>
   </td>
   <td>15 (10.4%)</td>
   <td>12 (11.8%)</td>
   <td>3 (6.9%)</td>
   <td>0.553</td>
  </tr>
  <tr>
   <td>
    <i>Headache</i>
   </td>
   <td>10 (6.9%)</td>
   <td>9 (8.9%)</td>
   <td>1 (2.3%)</td>
   <td>0.281</td>
  </tr>
  <tr>
   <td>
    <i>Insomnia</i>
   </td>
   <td>8 (5.5%)</td>
   <td>6 (5.9%)</td>
   <td>2 (4.6%)</td>
   <td>1.000</td>
  </tr>
  <tr>
   <td>
    <i>Amnesia</i>
   </td>
   <td>1 (0.7%)</td>
   <td>1 (0.9%)</td>
   <td>0</td>
   <td>1.000</td>
  </tr>
  <tr>
   <td>
    <i>Seizures</i>
   </td>
   <td>1 (0.7%)</td>
   <td>0</td>
   <td>1 (2.4%)</td>
   <td>0.298</td>
  </tr>
  <tr>
   <td>
    <b>Psychiatric symtomps,</b>
    <b>
     <i>n</i>
    </b>
    <b>(%)</b>
   </td>
   <td>8 (5.5%)</td>
   <td>8 (7.9%)</td>
   <td>0</td>
   <td>0.105</td>
  </tr>
  <tr>
   <td>
    <i>Anxiety</i>
   </td>
   <td>1 (0.7%)</td>
   <td>1 (0.9%)</td>
   <td>0</td>
   <td>1.000</td>
  </tr>
  <tr>
   <td>
    <i>Mood disorders</i>
   </td>
   <td>7 (4.8%)</td>
   <td>7 (6.9%)</td>
   <td>0</td>
   <td>0.103</td>
  </tr>
 </tbody>
 <tfoot>
  <p>
   <i>Legend:</i>
   <sup>a</sup>-rash, pruritus, photosensitivity; 
  </p>
  <p>
   <sup>b</sup>- diarrhea/constipation, dyspepsia, nausea; 
  </p>
  <p>
   <sup>c</sup>-hyper/hypotension, arrhythmias 
  </p>
 </tfoot>
</table>
